Childhood AML

Here you will find articles that discuss how children ages 0-18 can live their best life with an AML diagnosis and beyond. Each of these articles aim to empower children and their families to live healthfully and navigate an AML diagnosis. AML changes the way kids feel, eat, sleep and think. The articles here will help caregivers navigate these changes and provide you with information on how to overcome them. You will also find topics on living life after AML treatment such as returning to school, emotional support and tips for living as a childhood leukemia survivor.

Additionally, you will be kept up to date on the latest advances in AML that are specifically relevant to children who are 0-18 years old. You will learn about the latest FDA approvals for new drugs and treatment combinations that are indicated for childhood AML. You will also learn about newly published AML research studies and any advances or findings that may contribute to your child's AML treatment.

Understanding the Newly Discovered UBTF Mutation in Childhood AML

Childhood AML—March 28, 2022

Researchers at St. Jude’s Research Hospital have found that mapping the genome of pediatric cancer patients can help give precision care to those with a cancer diagnosis like AML. Because AML looks and behaves differently from child to child, tumor sequencing can give guidance in making overall treatment decisions that are unique to each patient. Read on to learn about the newly discovered UBTF mutation more commonly found among children with AML.

ASH 2021: Minimizing Cardiac Toxicity in Children with Acute Myeloid Leukemia

Childhood AML—December 12, 2021

Dr. Kasey Leger from Seattle Children’s Hospital presented her abstract titled: Minimizing Cardiac Toxicity in Children with Acute Myeloid Leukemia in an ASH session on Saturday. She reviews the risk of cardiotoxicity with AML treatment in children and strategies to lessen this risk.

Targeted Therapy Using Genome Mapping for Childhood AML and Other Pediatric Cancers

Childhood AML—October 5, 2021

Vyxeos Now FDA Approved for Children With Secondary AML

Childhood AML—May 19, 2021

The Food and Drug Administration (FDA) approves expanded use for Vyxeos (daunorubicin and cytarabine) that now includes the ability to treat newly diagnosed therapy-related childhood AML.

New Study Finds Higher Likelihood of AML in Children With Down Syndrome

Childhood AML—May 10, 2021

A new study published in the March issue of The Journal of Pediatrics found that children with Down Syndrome have an estimated 150-fold higher risk of developing AML before the age of five.